CT041治疗难治性转移性胰腺癌的安全性与疗效:两项早期试验的汇总分析
本文汇总分析了两项多中心、开放标签的I/Ib期试验(CT041-CG4006、CT041-ST-01),评估靶向claudin18.2的CAR-T疗法CT041在既往治疗过的胰腺癌患者中的安全性与疗效。合并队列共24例晚期胰腺癌患者,总体缓解率为16.7%,疾病控制率为70.8%,中位无进展生存期为3.3个月,中位总生存期为10.0个月。CT041表现出可耐受的安全性特征和令人鼓舞的抗肿瘤疗效信号,但观察到的缓解获益有待未来确认。
要点
- CT041在既往治疗进展的转移性胰腺癌患者中安全性可耐受,最常见≥3级不良事件为预处理相关血液学毒性。
- 总体缓解率16.7%,疾病控制率70.8%,中位无进展生存期3.3个月,中位总生存期10.0个月。
- 达到部分缓解/疾病稳定的患者中位PFS和OS较进展组延长,但缓解获益需未来确认。
核心结论
- 在既往治疗进展的转移性胰腺癌患者中,CT041表现出可耐受的安全性特征和令人鼓舞的抗肿瘤疗效信号。
- 此处观察到的缓解获益有待未来确认。
研究设计与样本
- 两项多中心、开放标签I/Ib期试验(CT041-CG4006、CT041-ST-01)的汇总分析,靶人群和评估计划相似。
- 合并队列共24例晚期胰腺癌患者,其中5例(20.8%)既往接受过一线治疗,19例(79.2%)接受过≥2线治疗。
- 主要目标为评估CT041的安全性和耐受性,次要目标包括疗效、药代动力学和免疫原性。
主要发现
- 最常见的≥3级治疗中出现的不良事件为预处理相关血液学毒性。
- 细胞因子释放综合征(CRS)和胃肠道疾病是最常报告的1级或2级不良事件。
- 总体缓解率为16.7%,疾病控制率为70.8%。
- 输注后中位无进展生存期(mPFS)为3.3个月(95% CI,1.8至6.2),中位总生存期(mOS)为10.0个月(95% CI,5.5至17.6)。
- 中位缓解持续时间(mDoR)为9.5个月(95% CI,2.6至未达到),12个月DoR率为50%(95% CI,5.8至84.5)。
关键数值与推荐
- 达到部分缓解/疾病稳定的患者中位PFS为6.0个月 vs 进展性疾病组1.0个月(P < .001),中位OS为17.6个月 vs 4.0个月(P < .001)。
- 17例(70.8%)患者的CA19-9水平降低至少30%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出此处观察到的缓解获益有待未来确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: CT041 is a chimeric antigen receptor (CAR)-modified T-cell therapy that specifically targets claudin18.2 in solid tumors. Here, we report the pooled analysis results of two exploratory clinical trials to evaluate CT041 in patients with previously treated pancreatic cancer (PC). PATIENTS AND METHODS: These two multicenter, open-label phase I/Ib trials (CT041-CG4006, CT041-ST-01) have a similar target population and evaluation schedule. The primary objective was to assess the safety and tolerability of CT041, whereas secondary objectives included efficacy, pharmacokinetics, and immunogenicity. RESULTS: The combined cohort comprised 24 patients with advanced PC. Among them, five patients (20.8%) had previously received one line of therapy, whereas 19 (79.2%) received ≥2 lines of therapy. The most common treatment-emergent adverse events of grade 3 or more were preconditioning-related hematologic toxicities. Cytokine release syndrome (CRS) and GI disorders were most reported grade 1 or 2 adverse events. The overall response rate and disease control rate were 16.7% and 70.8%. The median progression-free survival (mPFS) after infusion was 3.3 months (95% CI, 1.8 to 6.2), and the median overall survival (mOS) was 10.0 months (95% CI, 5.5 to 17.6). The median duration of response (mDoR)was 9.5 months (95% CI, 2.6 to Not reached), with a DoR rate at 12 months of 50% (95% CI, 5.8 to 84.5). The mPFS (6.0 v 1.0 months, P < .001) and mOS (17.6 v 4.0 months, P < .001) were prolonged in patients achieving partial response/stable disease than the progressive disease group. CA19-9 levels had reduced by at least 30% in 17 (70.8%) patients. CONCLUSION: In patients with metastatic PC after progression on previous therapy, CT041 demonstrated a tolerable safety profile and encouraging anticancer efficacy signals. Response benefit observed here needs to be ascertained in the future.
引用
- Qi C, Zhang P, Liu C, et al. Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials. J Clin Oncol. 2024. PMID: 38788174. doi:10.1200/JCO.23.02314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。